Literature DB >> 8737748

Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production.

J M Young1, S Panah, C Satchawatcharaphong, P S Cheung.   

Abstract

When freshly drawn, heparinized human whole blood is incubated with 50 microM calcium ionophore A23187, platelets are stimulated to produce thromboxane B2 (TxB2) by activation of prostaglandin G/H synthase-l (PGHS-1). TxB2 concentration, as measured by immunoassay, is maximal at 20-30 min and declines thereafter. Addition of acetylsalicylic acid (IC50 = 2.8 microM) or other nonsteroidal antiinflammatory drugs (NSAIDs) 15 min or 4.5h prior to 30 min stimulation with ionophore results in concentration dependent inhibition of TxB2 production. When blood is incubated with 0.01-10 micrograms/ml E. colilipopolysaccharide (LPS), PGHS-2 is induced and TxB2 levels become detectable at 3h and continue to increase through 24h. Using a 5h incubation with 10 micrograms/ml LPS, aspirin (10 microM added at 0 h), which is rapidly metabolized to salicylic acid, had no effect on 10 micrograms/ml LPS-induced TxB2, but inhibited TxB2 production by ionophore A23187 added at 4.5h through acetylation of pre-existing PGHS-1. In a 5h assay, NSAIDs added at 0 h were compared for inhibition of TxB2 production stimulated by addition of ionophore A23187 at 4.5h (PGHS-1), or by addition of LPS at 0 h (PGHS-2). Most NSAIDs were more potent against PGHS-1 than PGHS-2. Diclofenac, naproxen and flufenamic acid were equipotent or slightly selective for PGHS-2. Diflunisal and nimesulide were > 4-fold selective for PGHS-2, and NS-398 was > 30-fold selective for PGHS-2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737748     DOI: 10.1007/bf02259611

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  24 in total

1.  Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors.

Authors:  C J Grossman; J Wiseman; F S Lucas; M A Trevethick; P J Birch
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

2.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue.

Authors:  D A Kujubu; B S Fletcher; B C Varnum; R W Lim; H R Herschman
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

3.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.

Authors:  J Y Fu; J L Masferrer; K Seibert; A Raz; P Needleman
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

4.  Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression.

Authors:  L Feng; W Sun; Y Xia; W W Tang; P Chanmugam; E Soyoola; C B Wilson; D Hwang
Journal:  Arch Biochem Biophys       Date:  1993-12       Impact factor: 4.013

5.  Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase.

Authors:  B S Fletcher; D A Kujubu; D M Perrin; H R Herschman
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

6.  Human cyclooxygenase-2 cDNA.

Authors:  T Hla; K Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells.

Authors:  M J Holtzman; J Turk; L P Shornick
Journal:  J Biol Chem       Date:  1992-10-25       Impact factor: 5.157

8.  Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system.

Authors:  J Barnett; J Chow; D Ives; M Chiou; R Mackenzie; E Osen; B Nguyen; S Tsing; C Bach; J Freire
Journal:  Biochim Biophys Acta       Date:  1994-11-16

9.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

Authors:  N Futaki; S Takahashi; M Yokoyama; I Arai; S Higuchi; S Otomo
Journal:  Prostaglandins       Date:  1994-01

10.  Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1.

Authors:  K Glaser; M L Sung; K O'Neill; M Belfast; D Hartman; R Carlson; A Kreft; D Kubrak; C L Hsiao; B Weichman
Journal:  Eur J Pharmacol       Date:  1995-07-25       Impact factor: 4.432

View more
  9 in total

1.  Diminished lipoxin biosynthesis in severe asthma.

Authors:  Bruce D Levy; Caroline Bonnans; Eric S Silverman; Lyle J Palmer; Gautham Marigowda; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2005-06-16       Impact factor: 21.405

Review 2.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 3.  COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?

Authors:  L M Jackson; C J Hawkey
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

4.  Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.

Authors:  F Giuliano; T D Warner
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

5.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

Authors:  T D Warner; F Giuliano; I Vojnovic; A Bukasa; J A Mitchell; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

6.  A novel electron paramagnetic resonance-based assay for prostaglandin H synthase-1 activity.

Authors:  Catriona M Turnbull; Danny McClure; Adriano G Rossi; Ian L Megson
Journal:  J Inflamm (Lond)       Date:  2006-09-28       Impact factor: 4.981

7.  Flavonoids: Antiplatelet Effect as Inhibitors of COX-1.

Authors:  Cristina Zaragozá; Miguel Ángel Álvarez-Mon; Francisco Zaragozá; Lucinda Villaescusa
Journal:  Molecules       Date:  2022-02-08       Impact factor: 4.411

8.  Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1.

Authors:  Cristina Zaragozá; Francisco Zaragozá; Irene Gayo-Abeleira; Lucinda Villaescusa
Journal:  Molecules       Date:  2021-05-19       Impact factor: 4.411

Review 9.  Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability.

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2008       Impact factor: 5.228

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.